VECT VectivBio Holding AG

Biotech Analyst Ratings

Latest News

1. 09 May 2022 VectivBio to Participate at the Bank of America 2022 Healthcare Conference

   BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV. Company management will also be participating in one-on-one investor meetings at the conference on Wednesday, May 11, 2022.
   

   Bank of America 2022 Healthcare Conference
   Date: Wednesday, May 11, 2022
   Time: 4:40 p.m. PT / 7:40 p.m. ET
   Webcast: Click here

   An archived replay of the webcast will be available for 30 days following…

   View Full Article
2. 21 April 2022 VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

   BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Patrick Malloy as Senior Vice President, Investor Relations and Strategic Communications.  Mr. Malloy's two decades of investor relations and commercial leadership experience strengthens VectivBio as it continues to evolve into a fully integrated, rare disease leader. 
   

   "Pat has a broad range of experience in not only investor relations, but also commercial and strategic leadership in the biotech and rare disease spaces," said Luca Santarelli, M.D., Founder and CEO of VectivBio. "As we…

   View Full Article
3. 07 April 2022 VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

   Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022
   

   STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023

   Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase 3 Data

   Management to Host Conference Call Today at 8.00 a.m. ET

   BASEL, Switzerland, April 07, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today reported financial results and provided a business update for the full year ended December 31, 2021.

   "Since our…

   View Full Article
4. 30 March 2022 VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

   • Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide sales in Japan
   • Loan facility established with Kreos Capital, a leading global growth lender to life sciences and healthcare companies, granting the company access of up to $75 million, with a minimum commitment to draw down $10 million
   • VectivBio to hold FY 2021 Earnings Call and Business Update on April 7, 2022, at 8:00 a.m. ET
     

   BASEL, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational…

   View Full Article
5. 29 March 2022 VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference

   -- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease --
   

   -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies --

   BASEL, Switzerland, March 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today presented new clinical data demonstrating the potential of apraglutide, a next-generation, long-acting GLP-2 analog, as a novel treatment for short bowel syndrome with intestinal failure (SBS-IF) patients who have impaired renal function. The data were presented as a…

   View Full Article